As per the F&S Report, the company is one of the major manufacturers of Pharma Intermediates for certain key APIs, including Dolutegravir, Trazodone, Entacapone, Nintedanib and Rivaroxaban.

• Company, in consultation with the BRLMs, has undertaken a Pre-IPO Placement of Equity Shares aggregating to Rs. 100 crores. The size of the Fresh Issue has been reduced by Rs. 100 crores pursuant to the Pre-IPO Placement. Accordingly, the fresh issue size is up to Rs. 200 crores (The “Pre-IPO”)
  
• The bid/ offer will be open for subscription on Wednesday, September 01, 2021 and will get close on Friday, September 03, 2021.
  
• Company proposes to utilise the net proceeds of the Fresh Issue and the proceeds from the Pre-IPO Placement towards-
•  Repayment/prepayment of certain financial facilities availed by the Company;
  
• Funding working capital requirements of the Company; and
  
• General corporate purposes
  

•  The Company has developed and commercialised over 450 Pharma Intermediates for APIs and NCEs across 17 high growth therapeutic areas since inception
  

• GIDC, Sachin, Gujarat, spread over an aggregate land area of 8,250 sq. mtrs. with an installed capacity of 2,460.00 MTPA (“Sachin Facility”),
  
• GIDC, Ankleshwar Industrial Estate, Gujarat, spread over an aggregate land area of 10,644 sq. mtrs. with an installed capacity of 1,200.00 MTPA (“Ankleshwar Facility”), 
  
• GIDC Industrial Estate, Jhagadia, Gujarat, spread over an aggregate land area of 56,998.35 sq. mtrs with an installed capacity of 2,400.00 MTPA (“Jhagadia Facility” and together with Sachin Facility and Ankleshwar Facility, the “Manufacturing Facilities”).
  
• Capacity utilisation as percentage of total capacity was 63%, 46% and 36% for the FY 2021, 2020 and 2019 respectively
  

• To develop test and manufacture new products meeting regulatory standards subsequent to receipt of requisite regulatory approvals from the relevant authorities in India and overseas
  
• Make investments on an ongoing basis in new product launches and research and development for future products.
  
• To invest in development of products which are used in manufacture of APIs being used in formulations whose patents are expiring, which would lead to increase in demand for the Pharma Intermediates for such APIs.
  
• To foray further into the specialty chemicals sector enabling company to significantly diversify its existing product portfolio, with an objective of attaining inorganic expansion of business.
  

• The Company supply its products to 25 countries and have long standing relationships with numerous domestic and global pharmaceutical companies. It cater extensively to the large geographies of Italy, Finland, France and China,
  

• The Company has established long standing relationships with some of our key customers. Thirteen of our customers have been customers since the past 10 years and fifty of its customers have been customers since the past five years.
  

• The emerging market and developing economies are expected to lead the overall growth rebound, with the chemicals sector driving the growth story
• Several global players are opting for a “China + 1 offshore strategy”, with capacities shifting to cost efficient markets with strong technology capabilities like India
  
• Factors such as China’s stringent environmental regulations and increased cost of labor, Japan's announcement to offer incentives to industry from companies shifting base from China to India contribute in increasing market share for India.
  
• Market size and growth rates
  
•  The global chemicals market is valued at around USD 4,738 Bn in 2019, expected to grow at 6.2% CAGR; reaching USD 6,785 Bn by 2025
  
• China accounts for 40% market share followed by European Union at 14% and United States at 13%, India accounts for ~3.5% market share
  
• Indian chemicals market is valued at USD 166 billion (~4% share in the global chemical industry) in 2019, expected to reach ~USD 326 billion by 2025, with an anticipated growth of ~12% CAGR
  
• Specialty chemical industry forms ~47% of the domestic chemical market, which is expected to grow at a CAGR of around 11-12%.
  
• The market for Pharmaceutical intermediates in India for the year 2020 was estimated to be around USD 4.8 Bn, growing at a CAGR of 9.8% over 2015-20.
  
•  Key Growth Drivers for Industry
  
• Growing demand for generic drugs globally
  
• Rising Healthcare Expenditure
  
• Rise in construction projects across emerging markets and increased adoption of construction chemicals for improvement in quality of projects
  
• Demand for agricultural products for industrial applications such as in fuel blending and polymer manufacturing, opening up new avenues of applications for agrochemicals
  
• Company’s focus has been to develop cost effective processes for manufacturing its products
  
• The Company has filed eight process patent applications in relation to the same and three additional pending process patent applications for which applications were made recently, in March 2021 and
  
• The Company has developed significant expertise in chemistry and series of molecules

• Augmenting scale through organic and inorganic routes in the current geographic markets and expanding into new geographic markets – The Company may consider acquisition/ investment opportunities to selectively expand in other verticals.
  
• Such acquisitions will support our long-term strategy, strengthen its competitive position, particularly in acquiring technical expertise and provide greater scale to grow our earnings and increase shareholder value.
  
• Continue to focus on cost efficiency and improving productivity while employing environmentally friendly – The Company strongly believes in conducting its business operations in an environmentally responsible manner. It has set up a Zero Liquid Discharge based in-house effluent plant at our Sachin Unit.
  
• The Company intend to position itself as a leading market player in product verticals, both domestically and internationally by –
  
• Adopting the latest technological changes and be responsive to the constant technological upgradations and
  
• Emerging standards to ensure cost efficiency and environmentally friendly processes in its business operations.
  
• Diversification of business by focussing on organic and inorganic growth opportunities – The Company is in the process of building its synergies through inorganic acquisition and may in the future, use some of the land area available to us (which currently stands at 15,830.00 sq mtr, in our Jhagadia facility to explore brownfield expansion opportunities. The Company intends –
  
• To pursue strategic acquisitions and partnerships to complement our organic growth and internal expertise.
  
• To develop our internal capacities and production abilities to achieve intended levels of organic growth
  

• Revenue: Total revenue in fiscal 2021 increased by 41.03% amounting to Rs. 341.99 crores from Rs. 242.49 crores in fiscal 2020
  
• Company’s revenue from operations increased by 42.13% in fiscal 2021 amounting Rs. 340.61 crores from Rs. 239.64 crores in fiscal 2020. The increase was primarily due to –
  
• Increased sales of its products resulting from a robust growth of domestic and export demand
  
•  Pursuant to US FDA inspection of our Sachin facility in fiscal 2020, Company recorded growth in sale of intermediates used in manufacture of API in speciality chemical space that contributed to the revenue
  
• Pharma intermediary, Speciality Chemicals and others contributed 88.41%, 4.87% and 6.72% to the total revenue from operations in fiscal 2021
  
• Revenue from export in the total revenue of Pharma intermediary segment was 53.47% in fiscal 2021 compared to 46.52% in fiscal 2020
  
• Earnings before Interest Depreciation Tax & Amortisation: EBIDTA for fiscal 2021 amounted to Rs. 80.15 crores compared to Rs. 41.02 crores in fiscal 2020. EBIDTA margin for fiscal 2021 and fiscal 2020 was 23.53% and 17.12% respectively.
  
• Profit after Tax: PAT in fiscal 2021 increased 96.57% to Rs. 53.99 crores from Rs. 25.47 crores in fiscal 2020.  PAT margin was 15.70% in fiscal 2021 compared to 11.33% in fiscal 2020
  
• Earnings per share – EPS for fiscal 2021 was 17.14% compared to 8.72% in fiscal 2020
  
• Return on Capital employed- ROCE for fiscal 2021 was 25.25% compared to 22.40% in fiscal 202o
  
• Return on Equity – ROE for fiscal 2021 was 32.35% compared to 24.57% in fiscal 2020.